Statistics for In vitro evaluation of novel reverse transcriptase inhibitors TAF (tenofovir alafenamide) and OBP-601 (2,3-didehydro-3-deoxy-4-ethynylthymidine) against multi-drug resistant primary isolates of HIV-2
Total visits
| views | |
|---|---|
| In vitro evaluation of novel reverse transcriptase inhibitors TAF (tenofovir alafenamide) and OBP-601 (2,3-didehydro-3-deoxy-4-ethynylthymidine) against multi-drug resistant primary isolates of HIV-2 | 38 |
Total visits per month
| views | |
|---|---|
| November 2024 | 1 |
| December 2024 | 0 |
| January 2025 | 0 |
| February 2025 | 1 |
| March 2025 | 0 |
| April 2025 | 0 |
| May 2025 | 0 |
Top country views
| views | |
|---|---|
| United States | 13 |
| Portugal | 12 |
| Japan | 3 |
| Germany | 2 |
| Ireland | 2 |
| United Kingdom | 1 |
| South Korea | 1 |
| Singapore | 1 |
| Thailand | 1 |
| Ukraine | 1 |